Evidence map›Paper›PMID 41230809›Full record

ArticleJournal of cellular and molecular medicine2025

FGFR2 is a Crucial Factor for Adipose-Derived Mesenchymal Stem Cells in Promoting Diabetic Foot Ulcer Healing Through Angiogenesis.

Jing Cao, Zichao Liu, Wenqiang An, Xin Zhang, Zhujun Li, Lijie Li, Hailian Ji, Sen Zhang, Xiao Long, Yuemei Yang

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing CaoBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.ORCID 0009-0004-4651-0505
Zichao LiuBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.
Wenqiang AnBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.
Xin ZhangBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.
Zhujun LiDepartment of Plastic & Cosmetic Surgery, Peking Union Medical College Hospital, Beijing, China.
Lijie LiBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.
Hailian JiBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.
Sen ZhangInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiao LongDepartment of Plastic & Cosmetic Surgery, Peking Union Medical College Hospital, Beijing, China.ORCID 0000-0003-0136-2508
Yuemei YangBeijing AegleStem Therapeutics Co., Ltd, Beijing, China.

Funding

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-210National High Level Hospital Clinical Research Funding 2022-PUMCH-C-025National High Level Hospital Clinical Research Funding 2025-PUMCH-D-001Plastic Medicine Research Fund of Chinese Academy of Medical Sciences 2024-ZX-1-02the Zhongguancun National Independent Innovation Demonstration Zone Industrial Ecosystem Cultivation Project 20220468089
6 · The paper itself

Abstract

Diabetic foot ulcers (DFUs) remain a significant clinical challenge due to the lack of effective treatments, severely impacting patients' quality of life. Mesenchymal stem cells (MSCs) have shown potential in promoting DFU healing; however, the underlying mechanisms are not yet fully understood. This study investigates the role of adipose-derived mesenchymal stem cells (ADSCs) in DFU healing, with a particular focus on angiogenesis. Gene expression profiles from the GSE7014 and GSE80178 datasets in the Gene Expression Omnibus (GEO) database were analyzed. Differentially expressed genes (DEGs) were intersected with angiogenesis-related genes from the GeneCards database, identifying 35 angiogenesis-related DEGs (An-DEGs). Key genes were selected using Cytoscape software and machine learning. The pro-angiogenic effects of ADSCs were validated through in vivo and in vitro experiments, assessing their role in DFU healing. The DEGs from DFU patients were enriched in pathways such as angiogenesis and collagen-containing extracellular matrix. ADSCs promoted angiogenesis and wound healing by upregulating FGFR2 and secreting FGF, activating the FGF-PI3K/Akt-HIF-1α-VEGF axis. Additionally, ADSCs mediated secretion of VEGF concerting this effect. FGFR2 plays a pivotal role in ADSCs' mediated DFU healing by driving angiogenesis.

Indexed as

Adipose TissueDiabetic FootMesenchymal Stem CellsNeovascularization, PhysiologicReceptor, Fibroblast Growth Factor, Type 2Wound HealingAngiogenesisAnimalsHumansHypoxia-Inducible Factor 1, alpha SubunitMaleMesenchymal Stem Cell TransplantationMiceSignal TransductionFGFR2 protein, humanHypoxia-Inducible Factor 1, alpha SubunitReceptor, Fibroblast Growth Factor, Type 2adipose‐derived mesenchymal stem cellsangiogenesisdiabetic foot ulcersFGFR2

Identifiers

PMID41230809
PMCPMC12613079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.